Ads
related to: glucocerebrosidase treatment protocol for diabetes- Patient Profiles
Meet Stelo Patients.
Learn who benefits from Stelo.
- Explore Stelo
Over 25 years of innovation.
Technology from a company you trust
- Order Stelo
For your practice and bring the
benefit of Stelo to your patients.
- Provider Site
Empower Your Patients.
No Prescription Needed.
- Patient Profiles
Search results
Results from the WOW.Com Content Network
β-Glucocerebrosidase (also called acid β-glucosidase, D-glucosyl-N-acylsphingosine glucohydrolase, or GCase) is an enzyme with glucosylceramidase activity (EC 3.2.1.45) that cleaves by hydrolysis the β-glycosidic linkage of the chemical glucocerebroside, an intermediate in glycolipid metabolism that is abundant in cell membranes (particularly skin cells). [5]
Diabetes is very common. The Centers for Disease Control and Prevention (CDC) notes that 38.4 million people in the United States are currently living with diabetes. That’s 11.6 percent of the ...
It is a recombinant DNA-produced analogue of the human enzyme β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 and Type 3 [4] Gaucher's disease. It is available in formulations containing 200 or 400 ...
For those with type-I and most type-III, enzyme replacement treatment with intravenous recombinant glucocerebrosidase can decrease liver and spleen size, reduce skeletal abnormalities, and reverse other manifestations. [16] [29] This treatment costs about
The main goal of diabetes management is to keep blood glucose (BG) levels as normal as possible. [1] If diabetes is not well controlled, further challenges to health may occur. [1] People with diabetes can measure blood sugar by various methods, such as with a BG meter or a continuous glucose monitor, which monitors over several days. [2]
The first patient was treated using the Edmonton protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000. [1] The NEJM report was exciting for the diabetes field because the seven patients undergoing the Edmonton protocol remained insulin-independent after an average of 12 months. [citation ...
The typical treatment for SD is Botox injections into the larynx muscles. “You inject the muscles of the larynx with Botox, around the vocal folds, and it weakens the muscles,” Frankford says.
These include recognition that tight blood glucose control can slow or prevent diabetes complications, creation of treatment protocols to enable women with diabetes to have healthy babies, the identification of markers for pre-diabetes, and pioneering laser surgery for diabetic eye disease.
Ads
related to: glucocerebrosidase treatment protocol for diabetes